ARK Investment Management Reduces $39M in Veracyte, Inc. ($VCYT)
Key Points
- ARK Investment Management changed its Veracyte, Inc. ($VCYT) stake by 21.4% last quarter, cutting to 3,053,818 shares worth $144.54 million.
- Wall Street's consensus rating on $VCYT is Buy and an average price target of $49.10.
- $VCYT last traded around $47.33.
ARK Investment Management reduced its position in Veracyte, Inc. ($VCYT) by 21.4% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,053,818 shares of Veracyte, Inc. after selling 833,729 shares during the quarter. ARK Investment Management's holdings in Veracyte, Inc. were worth $144.54 million as of its most recent filing.
Veracyte, Inc. ($VCYT) Stock
Veracyte, Inc. Earnings
Analysts Set New Price Targets
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.